steroids used in ophthalmology, potency, moa, which drug causes how much increase in IOP, everything about it

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Searching PubMed

ophthalmic corticosteroids intraocular pressure steroid response

I now have comprehensive data from multiple authoritative sources. Let me compile the full answer.

Steroids in Ophthalmology - Complete Guide

1. Overview: Why Steroids Are Used in the Eye

Corticosteroids are the cornerstone of ocular anti-inflammatory therapy. Their uses include:

Anterior uveitis (AAU and chronic)
Post-operative inflammation (cataract, refractive, corneal, glaucoma filtering surgery)
Allergic conjunctivitis, vernal keratoconjunctivitis
Corneal chemical/radiation/thermal burns
Dry eye syndrome (severe)
Ocular cicatricial pemphigoid
Herpes zoster ophthalmicus (with antiviral cover)
Optic neuritis (IV methylprednisolone followed by oral taper)
Posterior uveitis (sub-Tenon's or systemic)
Diabetic macular edema and cystoid macular edema (intravitreal)
Sympathetic ophthalmia
After glaucoma filtering surgery - to delay wound healing and reduce bleb scarring

2. Mechanism of Action (MOA)

Corticosteroids act via multiple complementary mechanisms:

Genomic (slow, hours)

Bind intracellular glucocorticoid receptors (GR)
GR-steroid complex translocates to nucleus
Transactivation: upregulates anti-inflammatory proteins (annexin-1/lipocortin, IL-10)
Transrepression: suppresses NF-κB and AP-1, reducing transcription of pro-inflammatory cytokines (IL-1, IL-6, TNF-α, IL-2)

Non-genomic (rapid, minutes)

Direct membrane effects
Inhibit phospholipase A2 via annexin-1 → reduced arachidonic acid → reduced prostaglandins and leukotrienes
This is the key distinction from NSAIDs: steroids block both COX and LOX pathways

Cellular effects in the eye:

Decrease capillary permeability → reduce flare and cells in anterior chamber
Inhibit neutrophil and macrophage migration
Stabilize cell membranes
Reduce fibroblast activity (useful post-filtering surgery)
Inhibit VEGF (relevant in macular edema treatment)

3. Available Ophthalmic Steroids by Route

A. Topical (drops/ointments)

Drug	Formulation	Relative Potency	IOP Risk
Difluprednate (Durezol)	0.05% emulsion	Highest	High
Dexamethasone	0.1% susp/soln	Very high	High
Prednisolone acetate	0.12%, 1%	High	High
Prednisolone sodium phosphate	1%	High	High
Betamethasone	0.1%	Moderate-high	Moderate-high
Rimexolone (Vexol)	1%	Moderate	Lower
Fluorometholone (FML)	0.1%, 0.25%	Moderate-low	Lower
Loteprednol etabonate (Lotemax)	0.2%, 0.25%, 0.5%, 0.38% gel	Moderate-marked	Lowest

Key potency ranking (high → low IOP risk): Difluprednate > Dexamethasone ≈ Prednisolone acetate > Betamethasone > Rimexolone > Fluorometholone > Loteprednol

B. Periocular/Sub-Tenon's Injection

Triamcinolone acetonide - posterior uveitis, macular edema
Methylprednisolone acetate (Depo-Medrol) - periocular depot

C. Intravitreal

Drug	Dose	Duration of IOP risk	Indication
Triamcinolone acetonide (Kenalog, Trivaris)	4 mg/0.1 mL	2-4 months	Macular edema, uveitis, vitrectomy visualization
Dexamethasone intravitreal implant (Ozurdex)	0.7 mg	Up to 6 months	Macular edema (DME, RVO), uveitis
Fluocinolone acetonide implant (Retisert, Iluvien)	0.18-0.59 mg	Years (sustained)	Chronic non-infectious uveitis, DME

D. Systemic

IV Methylprednisolone 1 g/day x 3 days - optic neuritis (standard of care)
Oral Prednisolone - posterior uveitis, optic neuritis follow-up, giant cell arteritis (high dose)
Note: even nasal sprays, inhaled steroids, and dermatologic topical steroids can cause IOP elevation with prolonged use

4. Steroid-Induced IOP Elevation - Full Details

Mechanism of IOP Rise

The rise in IOP is due to increased resistance to aqueous outflow at the trabecular meshwork (TM):

Steroids alter extracellular matrix (ECM) of TM cells - accumulation of fibronectin, laminin, collagen
Inhibit matrix metalloproteinases (MMPs) → ECM builds up in TM → reduced outflow facility
Alter cytoskeleton of TM endothelial cells (increased actin stress fibers via GR-mediated effects)
Reduced phagocytic activity of TM cells
Some evidence for increased production of myocilin (MYOC gene) in TM, associated with POAG

The result is an open-angle glaucoma picture - angle is open on gonioscopy, but outflow facility is reduced.

Which Drug Causes How Much IOP Rise?

Drug / Route	% Patients with IOP Rise	Typical IOP Increase	Notes
Dexamethasone 0.1% topical	~30% responders in general population	Can raise IOP >10 mmHg in high responders	High-potency; highest topical IOP risk
Prednisolone acetate 1% topical	~30%	6-15+ mmHg in responders	First-line for uveitis; significant IOP risk
Difluprednate 0.05%	Similar to or exceeds prednisolone	Equivalent or higher IOP risk	More potent than prednisolone acetate
Betamethasone	~25-30%	Similar to prednisolone	Moderate-high risk
Fluorometholone 0.1%	~5-10%	Usually modest (<6 mmHg)	Much lower IOP risk; preferred for corneal/conjunctival conditions
Rimexolone 1%	~10-15%	Modest	Moderate, lower risk than prednisolone
Loteprednol etabonate	Lowest among topical steroids	Minimal in most patients	Metabolized to inactive compounds at the TM; "retrometabolic" design
Intravitreal triamcinolone	~30-40%	Can be significant; lasts 2-4 months after injection	Depot effect; harder to stop
Dexamethasone implant (Ozurdex)	~25-35%	IOP elevation may last up to 6 months	Sustained release
Fluocinolone implant (Iluvien)	Higher with long-term implant	Persistent elevation possible for years	~30-40% require IOP-lowering drugs; ~5% need surgery
Systemic/oral steroids	~5% without POAG family history; up to 90% with family history	Variable	Any route can cause IOP elevation

Population-level Steroid Response (Armaly-Becker Classification)

Low responders (~66% of population): IOP rise < 6 mmHg
Intermediate responders (~29%): IOP rise 6-15 mmHg
High responders (~5%): IOP rise > 15 mmHg

Approximately 1 in 3 individuals develop some degree of IOP elevation with potent topical steroids. The majority of POAG patients are steroid responders.

Timing

Onset: typically 2-4 weeks after starting topical/periocular steroids
Rarely, acute rise within hours with systemic steroids or ACTH
After intravitreal triamcinolone: lasts 2-4 months
After Ozurdex implant: up to 6 months
IOP usually returns to baseline after stopping - within days (acute form) or 1-4 weeks (chronic form)
In 3% of patients, elevated IOP persists permanently despite stopping all steroids (especially with family history of glaucoma)

Risk Factors for Steroid-Induced IOP Rise

Pre-existing glaucoma or ocular hypertension
Family history of glaucoma
High myopia
Young age (especially childhood - children are particularly sensitive)
Connective tissue disease, especially rheumatoid arthritis
Diabetes mellitus
African descent
Previous ocular trauma

5. Why Loteprednol Has the Lowest IOP Risk

Loteprednol etabonate is a "retrometabolic" steroid - it is a structural analogue of prednisolone that is designed to undergo predictable metabolism to inactive compounds. After it exerts its anti-inflammatory effect at the target tissue (conjunctiva, cornea), it is metabolized to Δ-1-cortienic acid etabonate and cortienic acid etabonate - both pharmacologically inactive. This limits systemic absorption and also reduces accumulation in the trabecular meshwork, explaining its lower IOP-elevating tendency.

6. Clinical Approach to Steroid Selection

For severe anterior uveitis: Prednisolone acetate 1% or dexamethasone 0.1% - start hourly, taper slowly over 5-6 weeks

For allergic conjunctivitis / mild inflammation: Fluorometholone 0.1% or loteprednol - adequate anti-inflammatory effect with low IOP risk

For post-operative inflammation (cataract): Prednisolone acetate 1% or difluprednate 0.05%

When IOP is already elevated or patient is a known steroid responder: Switch to fluorometholone, rimexolone, or loteprednol

For posterior uveitis / macular edema: Sub-Tenon's triamcinolone or intravitreal dexamethasone implant (Ozurdex)

Steroid-response glaucoma management:

Determine if steroid truly necessary - if not, stop/taper
Switch to lower-potency preparation (fluorometholone, loteprednol)
Add IOP-lowering drops (beta-blockers, prostaglandin analogues, alpha-2 agonists, carbonic anhydrase inhibitors)
Selective laser trabeculoplasty (SLT) can be effective
If depot injection is the cause and IOP is dangerously high, it may need surgical excision
After intravitreal steroid with persistent elevation - consider glaucoma filtering surgery or pars plana vitrectomy
Anterior chamber paracentesis for acute severe elevation

Post-LASIK note: Steroid-induced IOP elevation is difficult to detect after LASIK because applanation tonometry gives falsely low readings due to reduced corneal thickness or interface fluid. Measure peripheral to the flap for accuracy.

7. Other Ocular Side Effects of Steroids (Beyond IOP)

Posterior subcapsular cataract (PSC) - classic side effect with prolonged use; more common with systemic than topical
Secondary infections - bacterial, fungal, acanthamoeba, herpes simplex reactivation (HSV keratitis)
Corneal melting - especially with concurrent NSAID use
Delayed wound healing (a double-edged sword - exploited post-filtering surgery)
Systemic absorption - even topical can cause HPA axis suppression in children; advise medial canthal pressure after instillation

Sources:

Kanski's Clinical Ophthalmology: A Systematic Approach, 10th ed. - Steroid-induced glaucoma, Topical steroids sections
Wills Eye Manual - Section 9.9, Steroid-Response Glaucoma
Goodman & Gilman's The Pharmacological Basis of Therapeutics - Chapter 74, Glucocorticoids for Ophthalmic Use

This is a shared conversation. Sign in to Orris to start your own chat.